Home >Science >Health >COVID-19 vaccine: J&J’s Janssen vaccine gets $1 billion funding boost

Janssen Pharmaceutical Companies will expand its agreement with the US government’s Biomedical Advanced Research and Development Authority on the company’s development of a Covid-19 vaccine.

Janssen, a subsidiary of Johnson & Johnson, will invest about $604 million, while BARDA will commit about $454 million in additional money. Those funds will be used for Janssen’s Phase 3 ENSEMBLE trial evaluating the efficacy of the vaccine candidate.

“Combined with our own significant investment, this agreement has enabled our vital research and development and underscores the importance of public-private partnerships to tackle the worldwide Covid-19 pandemic," Paul Stoffels, M.D., chief scientific officer of Johnson & Johnson, said in a statement.

This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.

Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Never miss a story! Stay connected and informed with Mint. Download our App Now!!

Edit Profile
My ReadsRedeem a Gift CardLogout